Between January and October 2018, Russia imported 427.1 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 1.5% higher than that of the same period of 2017, and 87.9 bln RUB worth of in-bulk pharmaceuticals, which is in monetary terms 12.5% higher than that of the same period of 2017. In total, the dynamics in monetary terms are +3.2%.

In physical terms, Russia imported 1.5 bln units of ready-made pharmaceuticals, or 27.9 bln minimum dosage units (MDU.) The dynamics are -7.6% and -5.8%, respectively. The dynamics of the in-bulk import are +0.8% (3.5 bln MDU. The total import amounts to 31.5 bln units, with the dynamics being -5.1%.

In October 2018, Russia imported 50.1 bln RUB worth of ready-made pharmaceuticals, which is in monetary terms 4.4% higher than that of October 2017, and 6.7 bln RUB worth of in-bulk drugs, which is in monetary terms 16.2% lower than that of October 2017.

Among the top 20 companies with the biggest ready-made pharmaceutical drug import in monetary terms, MSD and Takeda have the highest dynamics. The dynamics of MSD are nearly +28%, with the import of follicle stimulating Purigon having increased by 89 times. The dynamics of Takeda are +25%. Its Alunbrig, used for lung cancer treatment, has not yet been registered in Russia and is imported only for certain patients for health reasons.

As for in-bulk importers, Merck Group and Concor have the biggest dynamics in monetary terms, with a 4.1 and 29 times increase, respectively. Amgen has also good dynamics (+300%), the import of its Vectibix, packaged by Russian Dobrolek, has increased by 5.6 times.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – October 2018)